Description
Key facts
Cell type:Jurkat,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 2 bp insertion, 1 bp insertion; Frameshift: 100%,
Disease:Non-Hodgkin Lymphoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IKZF1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Ikaros also known as IKZF1 is a transcription factor. You also find it being referred to as the Ikaros protein or Ikaros code. It has a molecular mass of about 58-60 kDa. Ikaros expresses mostly in hematopoietic cells including precursors from which various blood cell types derive. It plays a significant role in regulating gene expression and cellular differentiation modulating the chromatin structure to control access to DNA.
Biological function summary
Ikaros protein functions in the regulation of lymphoid cell development. It is a part of a chromatin-remodeling complex influencing chromatin accessibility. Through its zinc finger domains it binds to specific DNA sequences controlling genes necessary for lymphocyte differentiation and proliferation. Ikaros influences various cell types within the immune system especially affecting T and B cell development and also regulates cytokine receptor genes necessary for proper immune function.
Pathways
The Ikaros protein is critical to lymphocyte signaling pathways particularly the JAK/STAT and NF-κB pathways. In these pathways Ikaros interacts with other transcription factors like GATA3 and STAT5 integrating signals that are important for immune cell function and development. This integration allows a coordinated response to extracellular signals ensuring effective immune responses or tolerance.
Ikaros is associated with leukemia and lymphomas. Alterations or mutations in ikaros gene can lead to misregulation of its target genes contributing to the development of these diseases by disturbing normal hematopoietic processes. Moreover its interaction with TAL1 protein is significant in certain leukemias where disturbances in the balance of their activities can lead to malignancies. Understanding Ikaros’s role provides insights for therapeutic approaches in these blood disorders.
